RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

Corey A. Carter, Bryan T. Oronsky, Scott Z. Caroen, Jan J. Scicinski, Aiste Degesys, Michelle M. Kim, Arnold L. Oronsky, Harry Lybeck, Pedro Cabrales, Neil Oronsky, Tony Reid, Joseph Roswarski, Christina Brzezniak

Research output: Contribution to journalArticle

Abstract

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.

Original languageEnglish (US)
Pages (from-to)171-176
Number of pages6
JournalCase Reports in Oncology
DOIs
StateAccepted/In press - Mar 11 2016
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Platinum
Epigenomics
Phase II Clinical Trials
Neuroendocrine Tumors
Carboplatin
Etoposide
Non-Small Cell Lung Carcinoma
RRx-001
Therapeutics

Keywords

  • Epigenetic
  • Episensitization#
  • Platinum doublets
  • Resensitization
  • Resistance
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Carter, C. A., Oronsky, B. T., Caroen, S. Z., Scicinski, J. J., Degesys, A., Kim, M. M., ... Brzezniak, C. (Accepted/In press). RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. Case Reports in Oncology, 171-176. https://doi.org/10.1159/000444631

RRx-001 in Refractory Small-Cell Lung Carcinoma : A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. / Carter, Corey A.; Oronsky, Bryan T.; Caroen, Scott Z.; Scicinski, Jan J.; Degesys, Aiste; Kim, Michelle M.; Oronsky, Arnold L.; Lybeck, Harry; Cabrales, Pedro; Oronsky, Neil; Reid, Tony; Roswarski, Joseph; Brzezniak, Christina.

In: Case Reports in Oncology, 11.03.2016, p. 171-176.

Research output: Contribution to journalArticle

Carter, CA, Oronsky, BT, Caroen, SZ, Scicinski, JJ, Degesys, A, Kim, MM, Oronsky, AL, Lybeck, H, Cabrales, P, Oronsky, N, Reid, T, Roswarski, J & Brzezniak, C 2016, 'RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets', Case Reports in Oncology, pp. 171-176. https://doi.org/10.1159/000444631
Carter, Corey A. ; Oronsky, Bryan T. ; Caroen, Scott Z. ; Scicinski, Jan J. ; Degesys, Aiste ; Kim, Michelle M. ; Oronsky, Arnold L. ; Lybeck, Harry ; Cabrales, Pedro ; Oronsky, Neil ; Reid, Tony ; Roswarski, Joseph ; Brzezniak, Christina. / RRx-001 in Refractory Small-Cell Lung Carcinoma : A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. In: Case Reports in Oncology. 2016 ; pp. 171-176.
@article{98025905447641aa8c01a22bf3185795,
title = "RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets",
abstract = "RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.",
keywords = "Epigenetic, Episensitization#, Platinum doublets, Resensitization, Resistance, Small-cell lung cancer",
author = "Carter, {Corey A.} and Oronsky, {Bryan T.} and Caroen, {Scott Z.} and Scicinski, {Jan J.} and Aiste Degesys and Kim, {Michelle M.} and Oronsky, {Arnold L.} and Harry Lybeck and Pedro Cabrales and Neil Oronsky and Tony Reid and Joseph Roswarski and Christina Brzezniak",
year = "2016",
month = "3",
day = "11",
doi = "10.1159/000444631",
language = "English (US)",
pages = "171--176",
journal = "Case Reports in Oncology",
issn = "1662-6575",

}

TY - JOUR

T1 - RRx-001 in Refractory Small-Cell Lung Carcinoma

T2 - A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

AU - Carter, Corey A.

AU - Oronsky, Bryan T.

AU - Caroen, Scott Z.

AU - Scicinski, Jan J.

AU - Degesys, Aiste

AU - Kim, Michelle M.

AU - Oronsky, Arnold L.

AU - Lybeck, Harry

AU - Cabrales, Pedro

AU - Oronsky, Neil

AU - Reid, Tony

AU - Roswarski, Joseph

AU - Brzezniak, Christina

PY - 2016/3/11

Y1 - 2016/3/11

N2 - RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.

AB - RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.

KW - Epigenetic

KW - Episensitization#

KW - Platinum doublets

KW - Resensitization

KW - Resistance

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84961207551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961207551&partnerID=8YFLogxK

U2 - 10.1159/000444631

DO - 10.1159/000444631

M3 - Article

C2 - 27065849

AN - SCOPUS:84961207551

SP - 171

EP - 176

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

ER -